NAGE (Niagen Bioscience, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NAGE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-08 | Carlos Luis Lopez | SVP, General Counsel | A | — | — |
| 2026-07-08 | Ozan Pamir | Chief Financial Officer | A | — | — |
| 2026-07-08 | Robert N Fried | Chief Executive Officer | A | — | — |
| 2026-06-26 | Frank L Jr Jaksch | Director | A | — | — |
| 2026-06-26 | Kristin Patrick | Director | A | — | — |
| 2026-06-26 | Hamed Shahbazi | Director | A | — | — |
| 2026-06-26 | Wing Tak Wendy YU | Director | A | — | — |
| 2026-06-26 | Ann Cohen | Director | A | — | — |
| 2026-06-26 | Steven D Rubin | Director | A | — | — |
| 2026-06-26 | Wang Yu Gary Ng | Director | A | — | — |
| 2026-04-27 | Robert N Fried | Chief Executive Officer | M | — | — |
| 2026-02-24 | Ozan Pamir | Chief Financial Officer | A | — | — |
| 2026-02-24 | Carlos Luis Lopez | SVP, General Counsel | A | — | — |
| 2026-02-24 | Robert N Fried | Chief Executive Officer | A | — | — |
| 2025-11-17 | Ozan Pamir | Chief Financial Officer | Buy | — | — |
| 2025-07-03 | Hamed Shahbazi | Director | A | — | — |
| 2025-06-26 | Kristin Patrick | Director | A | — | — |
| 2025-06-26 | Wing Tak Wendy YU | Director | A | — | — |
| 2025-06-25 | Frank L Jr Jaksch | Director | A | — | — |
| 2025-06-25 | Wang Yu Gary Ng | Director | A | — | — |
| 2025-06-25 | Ann Cohen | Director | A | — | — |
| 2025-06-25 | Steven D Rubin | Director | A | — | — |
| 2025-04-09 | Robert N Fried | Chief Executive Officer | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 1,072,833 | — |
| — | Chief Financial Officer | 13,847 | — |
| — | SVP, General Counsel | 4,565 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NAGE quote page; the site-wide leaderboard is on the insider transactions hub.